Patients on multiple daily injections (MDI) insulin therapy and CGM saw greater A1C reduction than those on pump therapy and self-monitoring of blood glucose (SMBG).1
See why a continuous glucose monitoring (CGM) system is the right choice for optimizing your patient's diabetes treatment plan.
Medicare now provides coverage for therapeutic CGM systems (those approved for use in making diabetes treatment decisions). The Dexcom G5® CGM System is the first therapeutic CGM system covered as a Medicare benefit.
In its 11th year, ATTD is an International conference bringing together clinicians, such as diabetologists, endocrinologists as well as pediatricans and family medicine practitioners, scientists, engineers, start-ups, investors, medical...
Two leaders to combine tools aimed at reducing complexity and burden while improving outcomes in diabetes management
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people...
CGM Leader Introduces Public Application Programming Interface (API)
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (CGM), announced today the availability of a public API, empowering...
Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.
Battelino T, Phillip M, Bratina N, Nimri R, Oskarsson P, Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011;34(4):795-800.